Islet amyloid polypeptide in pancreatic islets from type 1 diabetic subjects

Islets

Volumn 3, Issue 4, 2011, Pages 166-174

  Tomita, Tatsuo ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Immunocytochemistry; Islet amyloid polypeptide; Pancreatic islets; Type 1 diabetes

Indexed keywords

AMYLIN; GLUCAGON; INSULIN; SOMATOSTATIN;

ARTICLE; CELL STRUCTURE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; PANCREAS ISLET; TISSUE REGENERATION;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CELL COUNT; CYTOPLASM; DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON; GLUCAGON-SECRETING CELLS; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ISLET AMYLOID POLYPEPTIDE; ISLETS OF LANGERHANS; MALE; MIDDLE AGED; ORGAN SIZE; REGENERATION; SOMATOSTATIN; SOMATOSTATIN-SECRETING CELLS;

EID: 79960106879     PISSN: 19382014     EISSN: 19382022     Source Type: Journal    
DOI: 10.4161/isl.3.4.15875     Document Type: Article

References (23)

1. Westermark P, Westermark C, Wilander E, Stetten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986; 140:827-31. (Pubitemid 17207764)
2. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreas of type 2 diabetic pancreas. Proc Natl Acad Sci USA 1987; 84:8627-31.
3. Kahn S, Andrilopuis S, Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 1999; 48:241-53. (Pubitemid 29061094)
4. Hooper JWM, Ahren B, Lips CM. Islet amyloid and type 2 diabetes mellitus. N Eng J Med 2000; 343:411-9. (Pubitemid 30626125)
5. Portala-Gomes GFM, Johansson H, Olding L, Grimelius L. Co-localization of neuroendocrine hormones in the fetal pancreas. Eur J Endocrinol 1999; 141:526-33.
6. Iki K, Pour PM. Distribution of pancreatic endocrine cells including IAPP-expressing cells in non-diabetic and type-2 diabetic cases. J Histochem Cytochem 2007; 55:111-8. (Pubitemid 46147688)
7. Verchere CB, D'Alessio DA, Pringeon R, Hill RL, Kahn SE. The constitutive pathway is a major route for islet amyloid polypeptide secretion in neonatal but not adult rat islet cells. Diabetes 2000; 49:1477-84.
8. Tingstedt JE, Edlund H, Madsen OD, Karssib LI. Gastric amylin expression: Cellular identity and lack of requirement for the hemeobox protein PDX-1 deficient animals with a cautionary note on antiserum evaluation. J Histochem Cytochem 1999; 47:973-80. (Pubitemid 29379896)
9. Kruger DF, Gatcomb PM, Owen SK. Clinical implications of amylin and amylin deficiency. Diabetes Educ 1999; 25:389-97.
10. Kolterman OG, Gottlieb A, Moyses C, Colburn W. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC 137, a human amylin analogue. Diabetes Care 1995; 18:1179-82.
11. Weyer C, Maggs DG, Young AA, Kolterman OG. Amylin replacement with Pramlintide as an adjuvant to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 2001; 7:1353-73. (Pubitemid 32798815)
12. Woods SC, Lutz TA, Geary N, Langhans W. Pancreatic signals controlling food intake, insulin, glucagon and amylin. Phil Trans R Soc 2006; 361:1219-35. (Pubitemid 44882937)
13. Labovitz HE. Adjunct therapy for type 1 diabetes mellitus. Nat Rev Endocrinol 1010; 6:326-34.
14. Buse JB, Weyer C, Maggs DG. Amylin replacement with Pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin Diabetes 2002; 20:137-44.
15. Fineman M, Weyer C, Maggs DG, Stobel S, Kolterman OG. The human amylin analog, Pramlintide reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Horm Metab Res 2002; 34:504-8.
16. Makimattilla S, Finemanm MS, Yki-Jarrivinen H. Deficiency of total and non-glycosylated amylin in plasm characterizes subjects with impaired glucose tolerance and type 2 diabetes. J Clini Endocrinol Metab 2000; 85:2822-7.
17. Hull RL, Westrmark GT, Westermark P, Kahn SE. Islet amyloid: a critical entity in pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 2004; 89:3629-43. (Pubitemid 39071447)
18. Lorenzo A, Razzabony B, Weir GC, Yankner BA. Pancreatic islet toxicity of amylin associated with type 2 diabetes mellitus. Nature 1994; 368:756-60. (Pubitemid 24153418)
19. Jaikaran E, Clark A. Islet amyloid and type 2 diabetes: from molecular, missfolding to islet pathophysiology. Biochem Biophy Acta 2001; 1537:179-203. (Pubitemid 33139801)
20. Marzbn A, Park K, Verchere CB. Islet amyloid polypeptide and type 2 diabetes. Exper Gerontol 2003; 38:347-51. (Pubitemid 36379069)
21. Kloppel G, Perren A, Heitz P. The gastrointestinal neuroendocrine cell system and its tumors. The WHO classification. Ann NY Acad Sci 2004; 1014:13-27. (Pubitemid 38594787)
22. Rindi G, Terenghi G, Westermark G, Wstermark P, Moscoso G, Polak J. Islet amyloid polypeptide in proliferating pancreatic B cells during develoment. Am J Pathol 1991; 138:1321-31.
23. Eissele R, Neuhaus C, Trautmann ME, Funk A, Arnold R, Hofler H. Immunoreacting and expression of amylin in gastropancreatic endocrin tumors. Am J Pathol 1993; 143:283-91. (Pubitemid 24058182)